Subject(s)
Infant, Premature , Purpura , Humans , Infant, Newborn , Purpura/diagnosis , Purpura/etiology , Female , Exanthema/diagnosis , Exanthema/etiology , MaleSubject(s)
IgA Vasculitis , Purpura , Skin Neoplasms , Humans , Purpura/diagnosis , Purpura/etiology , IgA Vasculitis/diagnosisSubject(s)
Peritoneal Dialysis , Purpura , Humans , Purpura/diagnosis , Purpura/etiology , Peritoneal Dialysis/adverse effects , PainABSTRACT
Pigmented purpuric dermatoses (PPD) encompass a group of chronic skin conditions characterized by the presence of petechiae, purpura, and pigmentation changes. While generally benign, these dermatoses can be persistent and aesthetically bothersome. Key clinical features include red to brownish patches with a distinctive "cayenne pepper" appearance, predominantly localized on the lower extremities, particularly the shins. Subtypes include Schamberg disease, Majocchi's disease, Gougerot-Blum disease, Ducas and Kapetanakis pigmented purpura, and lichen aureus. Diagnosis relies primarily on clinical evaluation of skin lesions, with biopsy as a confirmatory tool. Although the exact cause of PPD remains unclear, capillary fragility and red blood cell extravasation are implicated. Treatment strategies for PPD aim to alleviate symptoms, considering the generally benign and chronic nature of the condition. As there is no standardized treatment, various methods with varying efficacy are employed. After searching SCOPUS and PubMed databases, we assessed 42 original articles to present current knowledge regarding therapy of PPD. This review will compare treatment approaches specifically in Schamberg disease and other manifestations of pigmented purpuric dermatoses.
Subject(s)
Eczema , Pigmentation Disorders , Purpura , Skin Diseases , Vascular Diseases , Humans , Pigmentation Disorders/etiology , Skin Diseases/diagnosis , Purpura/diagnosis , Purpura/etiology , Purpura/pathology , Vascular Diseases/complicationsABSTRACT
Tumor necrosis factor alpha (TNFα) inhibitors are now widely used to treat immune-mediated inflammatory diseases. Although they have a good safety profile, they are also associated with adverse cutaneous events. Pigmented purpuric dermatoses (PPD) include a variety of skin diseases characterized by multiple petechial hemorrhages due to capillaritis. Five major clinical types of PPD have been described and purpura annularis telangiectodes of Majocchi (PATM) is a rare subtype of PPD. The cause of PPD is unknown, but drugs are implicated in a minority of cases. There are very few cases in the literature triggered by TNFα inhibitors. We present a case of PATM induced by certolizumab pegol and perform a review including 4 articles in the literature reporting 5 PPD cases induced by TNFα inhibitors. When purpuric eruptions develop in patients treated with TNFα inhibitors, PPD and vasculitis should be differentiated. Thus, patients are not exposed to unnecessary evaluations and treatments.
Subject(s)
Pigmentation Disorders , Purpura , Humans , Certolizumab Pegol/adverse effects , Tumor Necrosis Factor-alpha , Skin/pathology , Purpura/chemically induced , Purpura/diagnosis , Purpura/complicationsABSTRACT
Purpuric or erythematous eruptions of the lower extremities can be perplexing, especially because this clinical sign has been associated with COVID-19 infection. Since the start of the pandemic, COVID-19 often has been the first differential diagnosis for many clinical findings; however, pigmented purpuric dermatoses (PPDs) are distinctive, reassuring, eponymous, and not linked to this virus. In this article, we differentiate the PPDs and delineate them from potentially serious differential diagnoses, including inflammatory retiform purpura, leukocytoclastic vasculitis, stasis dermatitis, and cellulitis.
Subject(s)
COVID-19 , Eczema , Purpura , Humans , COVID-19/complications , COVID-19/diagnosis , Purpura/diagnosis , Purpura/etiology , Cellulitis , Diagnosis, DifferentialSubject(s)
Exanthema , Purpura , Humans , Leg , Purpura/diagnosis , Purpura/etiology , Lower Extremity , Exanthema/etiologySubject(s)
Humans , Male , Middle Aged , Leg/pathology , Pruritus/diagnosis , Purpura/diagnosis , BiopsySubject(s)
Humans , Male , Middle Aged , Pruritus/diagnosis , Purpura/diagnosis , Leg/pathology , BiopsyABSTRACT
OBJECTIVE: To determine the incidence and clinical predictors of invasive bacterial infection (IBI) in well-appearing children who present to the emergency department (ED) with fever and petechiae. DESIGN: A prospective, observational, multicentre study was conducted in 18 hospitals between November 2017 and October 2019. PATIENTS: A total of 688 patients were recruited. MAIN OUTCOME MEASURES: The primary outcome was the presence of IBI. Clinical features and laboratory test results were described and related to the presence of IBI. RESULTS: Ten IBIs were found (1.5%), comprising eight cases of meningococcal disease and two of occult pneumococcal bacteraemia. Median age was 26.2 months (IQR 15.3-51.2). Blood samples were obtained from 575 patients (83.3%). Patients with an IBI had a shorter time from fever to ED visit (13.5 hours vs 24 hours) and between fever and rash onset (3.5 hours vs 24 hours). Values for absolute leucocyte count, total neutrophil count, C reactive protein and procalcitonin were significantly higher in patients with an IBI. Significantly fewer patients with a favourable clinical status while in the observation unit were found to have an IBI (2/408 patients, 0.5%) than when clinical status was unfavourable (3/18, 16.7%). CONCLUSIONS: The incidence of IBI among children with fever and petechial rash is lower than previously reported (1.5%). The time from fever to ED visit and to rash onset was shorter in patients with an IBI. Patients with a favourable clinical course during observation in the ED are at lower risk of IBI.
